SUBCHONDRAL SOLUTIONS SECURES SERIES C FUNDING TO FURTHER EXPAND ITS ORTHOPEDIC SOLUTION  

Subchondral Solutions Series C Funding Release_June 2022
Subchondral Solutions Series C Funding Release_June 2022

Contacts:

Jay Geer: 562-883-0375

jay@millergeer.com

Rick Damrel: 562-900-5123

rick@millergeer.com

 

SUBCHONDRAL SOLUTIONS SECURES SERIES C FUNDING TO FURTHER EXPAND ITS ORTHOPEDIC SOLUTION

 

HUNTINGTON BEACH, CALIF., (June 6, 2022) — Subchondral Solutions, Inc., an orthopedic medical device company based in Huntington Beach, Calif., has announced closure of its Series C funding.  Subchondrals’s S-Core® platform technology™ is an innovative delivery platform for subchondral bone damage in most joints to help restore biomechanical function. S-Core® Implants are coated with hydroxyapatite to maximize bone and biologic healing.

The Series C round of financing was led by Eli Spiro, CEO of Axxcess Capital. Carlsbad, California – based Axxcess Capital Partners, LLC, is a boutique investment bank providing advisory services to companies seeking capital solutions.

“Eli and his team have been perfect financial partners for Subchondral Solutions during our rapid commercial growth,” says Thomas Kinder, CEO of Subchondral Solutions. “Our S-Core® device is quickly becoming a significant player in the foot and ankle and orthopedic sports medicine markets and will soon be expanding into upper extremities.”

Cleared by the FDA in 2020, the S-Core® delivery platform is indicated for the fixation of small bone fragments, such as osteochondral fragments and cancellous fragments, appropriate for the size of the damage area which may include the following: simple metaphyseal fractures; condylar fractures; osteochondritis dissecans; areas where accurate implant placement is vital; patellar fractures, navicular fractures, cancellous bone fragments; osteochondral fragments, intra-articular fractures and osteochondral fixation and fractures, and minimally invasive reconstruction of fractures and joints.

“S-Core® provides a novel solution”

“S-Core® provides a novel solution,” says Jordan Peana, Subchrondral’s vice-president of sales.  “Our technology helps to rapidly reduce pain while preserving the motion in the joint and extending the active lifestyle of the patient.”

S-Core® can be used in any osteochondral fracture appropriate for the size of the device, including for the knee, elbow, hand, foot, ankle and shoulder.

 

###

About Subchondral Solutions, Inc.

Subchondral Solutions was formed in 2013 and is committed to advancing the treatment of joint damage by addressing the source of the problem with a biomechanical, efficient, cost-effective scalable system. Contact us at sales@subchondralsolutions.com or online at subchondralsolutions.com